|Last Price$166.35||Day Change (%)-0.04%|
|Open Price$165.97||Day Change ($)-0.07|
|Day Range163.11–166.63||52-Week Range127.10–220.86|
As of Fri 7/29/2016 5:00:00 PM | USD
Illumina to Announce Second Quarter 2016 Financial Results on Tuesday, July 26, 2016
Global Genetic Testing Market Report 2016-2022 - Analysis, Technologies & Forecasts - Key Vendors: Abbott Labs, Roche Diagnostics, Myriad Genetics - Research and Markets
UPDATE: Why knowing your genetic data can be a tricky proposition
Illumina ILMN reported second-quarter results Tuesday that beat our expectations, and we plan to raise our fair value estimate by several dollars per share. Revenue totaled $84.5 million for the quarter, a 103% increase from the year-ago period, which prompted the firm to significantly raise its ...
Continued technology advancements and market expansion support Illumina's narrow moat.
Nucleic Acid Purification Market 2016: New Life Science Dashboard™ from Percepta observes decreased number of end-users but projects unit growth in the dynamic $1 Billion market in North America and Europe
Competitive advantages have improved for Mead Johnson, while De La Rue's moat was downgraded to narrow and POSCO was deemed a no-moat company.
Recent deals have been driven more by tax strategies than therapeutic synergies.
While a majority of our top fund managers are outperforming this year, five of them truly stand out from the rest given their ability to outperform the market over all time periods.
Ownership data provide a look at who else owns the company.